Cidara Therapeutics Inc (NASDAQ: CDTX) stock closed at $12.60 on 10/25/24 after a major increase of 12.9%. Moreover, exceptionally high trading volume at 369% of normal accompanied the advance. Relative to the market the stock has been weak over the last nine months but has risen 13.0% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, CDTX is expected to continue to be Value Creation neutral.
Cidara Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment